Literature DB >> 27821508

Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research.

Patrick T McGann1, Arielle G Hernandez1, Russell E Ware1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27821508      PMCID: PMC5234214          DOI: 10.1182/blood-2016-09-702324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  75 in total

1.  Complications of sickle cell anaemia in children in Northwestern Tanzania.

Authors:  Hamza Saidi; Luke R Smart; Erasmus Kamugisha; Emmanuela E Ambrose; Deogratias Soka; Robert N Peck; Julie Makani
Journal:  Hematology       Date:  2016-02-17       Impact factor: 2.269

2.  A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies.

Authors:  Charles T Quinn; Mary C Paniagua; Robert K DiNello; Anand Panchal; Mark Geisberg
Journal:  Br J Haematol       Date:  2016-09-08       Impact factor: 6.998

3.  Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.

Authors:  Susanna Bortolusso Ali; Michelle Moosang; Lesley King; Jennifer Knight-Madden; Marvin Reid
Journal:  Am J Hematol       Date:  2011-09-02       Impact factor: 10.047

4.  Stroke prevalence amongst sickle cell disease patients in Nigeria: a multi-centre study.

Authors:  Madu Anazoeze Jude; Galadanci Najiba Aliyu; Aisha Mohammed Nalado; Kangiwa Umar Garba; Fowodu O Florence; Ahmed Hassan; Marcus Inyama; Oluwaseun Akinpelu; Nwagha Theresa; Ibegbulam Obike Godswill; Ocheni Sunday; Emodi Ifeoma; Ikefuna Anthony; Chukwu Batholomew; Okocha E Chide; Orkuma Joseph; Iheanacho Malachy; Kaladada Korubo; Anike Uchenna Sabastine; Agu Kingsley; Charles Nonyelu; Angela Ugwu; Augustin Duru; Chukwudi Anigbo; Alozie Eze; Awele Chukwurah; Uchenna Ololo; Caroline Omoti; Obineche Agwu; Okpala Iheanyi
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

5.  Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II.

Authors:  J M Falletta; G M Woods; J I Verter; G R Buchanan; C H Pegelow; R V Iyer; S T Miller; C T Holbrook; T R Kinney; E Vichinsky
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

6.  Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.

Authors:  Natasha B Halasa; Sadhna M Shankar; Thomas R Talbot; Patrick G Arbogast; Ed F Mitchel; Winfred C Wang; William Schaffner; Allen S Craig; Marie R Griffin
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

7.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Antonios Bilalis; Eleni Plata; Konstantinos Varvagiannis; George Stamatopoulos; Klio Sinopoulou; Aggeliki Balassopoulou; Dimitris Loukopoulos; Evangelos Terpos
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

Review 8.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Authors:  F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

Review 9.  Problems and Approaches for Blood Transfusion in the Developing Countries.

Authors:  David J Roberts; Stephen Field; Meghan Delaney; Imelda Bates
Journal:  Hematol Oncol Clin North Am       Date:  2016-04       Impact factor: 3.722

10.  Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.

Authors:  Juliana N Anyanwu; Olatundun Williams; Casey L Sautter; Phillip Kasirye; Heather Hume; Robert O Opoka; Teresa Latham; Christopher Ndugwa; Russell E Ware; Chandy C John
Journal:  JMIR Res Protoc       Date:  2016-06-23
View more
  31 in total

1.  Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.

Authors:  Léon Tshilolo; George Tomlinson; Thomas N Williams; Brígida Santos; Peter Olupot-Olupot; Adam Lane; Banu Aygun; Susan E Stuber; Teresa S Latham; Patrick T McGann; Russell E Ware
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.

Authors:  Patrick T McGann; Thomas N Williams; Peter Olupot-Olupot; George A Tomlinson; Adam Lane; José Luís Reis da Fonseca; Robert Kitenge; George Mochamah; Ham Wabwire; Susan Stuber; Thad A Howard; Kathryn McElhinney; Banu Aygun; Teresa Latham; Brígida Santos; Léon Tshilolo; Russell E Ware
Journal:  Am J Hematol       Date:  2018-01-27       Impact factor: 10.047

Review 3.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

Review 4.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

5.  Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.

Authors:  Robert O Opoka; Heather A Hume; Teresa S Latham; Adam Lane; Olatundun Williams; Jennifer Tymon; Maria Nakafeero; Phillip Kasirye; Christopher M Ndugwa; Chandy C John; Russell E Ware
Journal:  Haematologica       Date:  2019-10-24       Impact factor: 9.941

Review 6.  The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.

Authors:  Boshen Jiao; Anirban Basu; Joshua Roth; M Bender; Ilsa Rovira; Traci Clemons; Dalyna Quach; Scott Ramsey; Beth Devine
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981

7.  Empowering newborn screening programs in African countries through establishment of an international collaborative effort.

Authors:  Bradford L Therrell; Michele A Lloyd-Puryear; Kwaku Ohene-Frempong; Russell E Ware; Carmencita D Padilla; Emmanuela E Ambrose; Amina Barkat; Hassan Ghazal; Charles Kiyaga; Tisungane Mvalo; Obiageli Nnodu; Karim Ouldim; Mohamed Chérif Rahimy; Brígida Santos; Léon Tshilolo; Careema Yusuf; Guisou Zarbalian; Michael S Watson
Journal:  J Community Genet       Date:  2020-05-15

8.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694

9.  "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Authors:  Titilola S Akingbola; Bamidele O Tayo; Chinedu A Ezekekwu; Omowunmi Sonubi; Xu Zhang; Santosh L Saraf; Robert Molokie; Lewis L Hsu; Jin Han; Richard S Cooper; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2019-02-06       Impact factor: 10.047

10.  Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Authors:  Bamidele O Tayo; Titilola S Akingbola; Santosh L Saraf; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2018-05-14       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.